Base de dados : MEDLINE
Pesquisa : A05.360.319.679.256 [Categoria DeCS]
Referências encontradas : 21200 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2120 ir para página                         

  1 / 21200 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28954299
[Au] Autor:Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group
[Ad] Endereço:Roche Molecular Diagnostics, Pleasanton, CA; National Cancer Institute, National Institutes of Health, Bethesda, MD; HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD; Agencia Costarricense de Investigaciones Biomédicas (ACI
[Ti] Título:Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
[So] Source:J Natl Cancer Inst;110(2), 2018 Feb 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Previously, we demonstrated similar human papillomavirus (HPV)16/18 vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination in a nonrandomized analysis of women who received a varying number of doses of the bivalent HPV16/18 vaccine. Here we extend data to seven years following initial vaccination. Methods: We evaluated HPV16/18-vaccinated women who received one (n = 134), two (n 0/1 = 193, n 0/6 = 79), or three doses (n = 2043) to a median of 6.9 years postvaccination. Cervical HPV DNA was measured with the SPF10- DEIA-LiPA PCR system; HPV16/18-specific antibody levels were measured using enzyme-linked immunosorbent assays (n = 486). Infection and immunological measures were compared across vaccine dose groups. Prevalent HPV infection at year 7 was also compared with an unvaccinated control group (UCG). All statistical tests were two-sided. Results: Among women in the three-dose, two-dose 0/6 , two-dose 0/1 , and one-dose groups, cumulative incident HPV16/18 infection rates (No. of events/No. of individuals) were 4.3% (88/2036, 95% confidence interval [CI] = 3.5% to 5.3%), 3.8% (3/78, 95% CI = 1.0% to 10.1%), 3.6% (7/192, 95% CI = 1.6% to 7.1%), and 1.5% (2/133, 95% CI = 0.3% to 4.9%; P = 1.00, .85, .17 comparing the two-dose 0/6 , two-dose 0/1 , and one-dose groups to the three-dose group, respectively). The prevalence of other carcinogenic and noncarcinogenic HPV types, excluding HPV16/18/31/33/45, were high and not statistically different among all dose groups, indicating that the low incidence of HPV16/18 in the one- and two-dose groups was not due to lack of exposure. At seven years, 100% of participants in all dose groups remained HPV16 and HPV18 seropositive. A non-statistically significant decrease in the geometric mean of the HPV16 antibody levels between years 4 and 7 was observed among women in the three-dose group: -10.8% (95% CI = -25.3% to 6.6%); two-dose (0/6 months) group: -17.3% (95% CI = -39.3% to 12.8%), two-dose (0/1 month) group: -6.9% (95% CI = -22.1% to 11.2%), and one-dose group: -5.5% (95% CI = -29.7% to 27.0%); results were similar for HPV18. Conclusions: At an average of seven years of follow-up, we observed similar low rates of HPV16/18 infections and slight, if any, decreases in HPV16/18 antibody levels by dose group.
[Mh] Termos MeSH primário: Papillomavirus Humano 16/imunologia
Papillomavirus Humano 18/imunologia
Vacinas contra Papillomavirus/administração & dosagem
Vacinas contra Papillomavirus/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Colo do Útero/virologia
DNA Viral/genética
Feminino
Papillomavirus Humano 16/genética
Papillomavirus Humano 18/genética
Seres Humanos
Infecções por Papillomavirus/imunologia
Infecções por Papillomavirus/prevenção & controle
Infecções por Papillomavirus/virologia
Doenças do Colo do Útero/imunologia
Doenças do Colo do Útero/prevenção & controle
Doenças do Colo do Útero/virologia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (DNA, Viral); 0 (Papillomavirus Vaccines); 0 (human papillomavirus vaccine, L1 type 16, 18)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx158


  2 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29260226
[Au] Autor:Saccone G; Maruotti GM; Giudicepietro A; Martinelli P; Italian Preterm Birth Prevention (IPP) Working Group
[Ad] Endereço:Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
[Ti] Título:Effect of Cervical Pessary on Spontaneous Preterm Birth in Women With Singleton Pregnancies and Short Cervical Length: A Randomized Clinical Trial.
[So] Source:JAMA;318(23):2317-2324, 2017 12 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Spontaneous preterm birth is a major cause of perinatal morbidity and mortality. It is unclear if a cervical pessary can reduce the risk of spontaneous preterm delivery. Objective: To test whether in asymptomatic women with singleton pregnancies and no prior spontaneous preterm birth but with short cervical length on transvaginal ultrasound, use of a cervical pessary would reduce the rate of spontaneous preterm birth at less than 34 weeks of gestation. Design, Setting, and Participants: Parallel-group, nonblinded, randomized clinical trial conducted from March 1, 2016, to May 25, 2017, at a single center in Italy. Asymptomatic women with singleton gestations, no previous spontaneous preterm births, and cervical lengths of 25 mm or less at 18 weeks 0 days to 23 weeks 6 days of gestation were eligible. Interventions: Patients were randomized 1:1 to receive either cervical pessary (n = 150) or no pessary (n = 150). The pessary was removed between 37 weeks 0 days and 37 weeks 6 days of gestation or earlier if clinically indicated. The control group received standard care. For cervical length of 20 mm or shorter, women in both groups were prescribed vaginal progesterone, 200 mg/d, until 36 weeks 6 days of gestation. No bed rest or activity restriction was recommended. Main Outcomes and Measures: The primary end point was spontaneous preterm birth at less than 34 weeks of gestation. Secondary outcomes were adverse events. Results: Among 300 women who were randomized (mean age, 29 [SD, 6.3] years; mean gestational age, 22 [SD, 1.3] weeks), 100% completed the trial. The primary end point occurred in 11 women (7.3%) in the pessary group and 23 women (15.3%) in the control group (between-group difference, -8.0% [95% CI, -15.7% to -0.4]; relative risk, 0.48 [95% CI, 0.24-0.95]). During follow-up, the pessary group had a higher rate of increased or new vaginal discharge (86.7% vs 46.0%; between-group difference, +40.7% [95% CI, +30.1%-+50.3%]; relative risk, 1.88 [95% CI, 1.57-2.27]). Conclusions and Relevance: Among women without prior spontaneous preterm birth who had asymptomatic singleton pregnancies and short transvaginal cervical length, use of a cervical pessary, compared with no pessary use, resulted in a lower rate of spontaneous preterm birth at less than 34 weeks of gestation. The results of this single-center, nonblinded study among selected pregnant women require confirmation in multicenter clinical trials. Trial Registration: clinicaltrials.gov Identifier: NCT02716909.
[Mh] Termos MeSH primário: Colo do Útero/anatomia & histologia
Pessários
Nascimento Prematuro/prevenção & controle
[Mh] Termos MeSH secundário: Administração Intravaginal
Adulto
Medida do Comprimento Cervical
Terapia Combinada
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Gravidez
Progesterona/uso terapêutico
Progestinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Progestins); 4G7DS2Q64Y (Progesterone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171221
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.18956


  3 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29346438
[Au] Autor:Sierra LJ; Brown AG; Barilá GO; Anton L; Barnum CE; Shetye SS; Soslowsky LJ; Elovitz MA
[Ad] Endereço:Maternal Child Health Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
[Ti] Título:Colonization of the cervicovaginal space with Gardnerella vaginalis leads to local inflammation and cervical remodeling in pregnant mice.
[So] Source:PLoS One;13(1):e0191524, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The role of the cervicovaginal (CV) microbiome in regulating cervical function during pregnancy is poorly understood. Gardnerella vaginalis (G. vaginalis) is the most common bacteria associated with the diagnosis of bacterial vaginosis (BV). While BV has been associated with preterm birth (PTB), clinical trials targeting BV do not decrease PTB rates. It remains unknown if G. vaginalis is capable of triggering molecular, biomechanical and cellular events that could lead to PTB. The objective of this study was to determine if cervicovaginal colonization with G. vaginalis, in pregnant mice, induced cervical remodeling and modified cervical function. CD-1 timed-pregnant mice received a 5X108 CFU/mL intravaginal inoculation of G. vaginalis or control on embryonic day 12 (E12) and E13. On E15, the mice were sacrificed and cervicovaginal fluid (CVF), amniotic fluid (AF), cervix, uterus, placentas and fetal membranes (FM) were collected. Genomic DNA was isolated from the CVF, placenta, uterus and FM and QPCR was performed to confirm colonization. IL-6 was measured in the CVF and AF and soluble e-cadherin (seCAD) was assessed in the CVF by ELISA. RNA was extracted from the cervices to evaluate IL-10, IL-8, IL-1ß, TNF-α, Tff-1, SPINK-5, HAS-1 and LOX expression via QPCR. Mucicarmine and trichrome staining was used to assess cervical mucin and collagen. Biomechanical properties of the cervix were studied using quasi-static tensile load-to-failure biomechanical tests. G. vaginalis successfully colonized the CV space. This colonization induced immune responses (increased IL-6 levels in CVF and AF, increased mRNA expression of cervical cytokines), altered the epithelial barrier (increased seCAD in the CVF), induced cervical remodeling (increased mucin production, altered collagen) and altered cervical biomechanical properties (a decrease in biomechanical modulus and an increase in maximum strain). The ability of G. vaginalis to induce these molecular, immune, cellular and biomechanical changes suggests that this bacterium may play a pathogenic role in premature cervical remodeling leading to PTB.
[Mh] Termos MeSH primário: Colo do Útero/microbiologia
Gardnerella vaginalis/isolamento & purificação
Inflamação/microbiologia
Vagina/microbiologia
[Mh] Termos MeSH secundário: Animais
Fenômenos Biomecânicos
Colo do Útero/patologia
Citocinas/metabolismo
Ensaio de Imunoadsorção Enzimática
Feminino
Gardnerella vaginalis/genética
Gardnerella vaginalis/crescimento & desenvolvimento
Camundongos
Gravidez
Reação em Cadeia da Polimerase em Tempo Real
Vaginose Bacteriana/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cytokines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180119
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191524


  4 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29209810
[Au] Autor:Tang Z; Xu Y; Song N; Zou D; Liao Y; Li Q; Pan C
[Ad] Endereço:Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China.
[Ti] Título:A comparison of the MeltPro HPV Test with the Cobas HPV Test for detecting and genotyping 14 high-risk human papillomavirus types.
[So] Source:Arch Virol;163(3):725-730, 2018 Mar.
[Is] ISSN:1432-8798
[Cp] País de publicação:Austria
[La] Idioma:eng
[Ab] Resumo:The clinical performance of the newly developed MeltPro HPV Test, based on multicolor melting curve analysis, was evaluated and compared with the commercially available Cobas HPV Test for detection of HPV and genotyping of HPV-16 and HPV-18. A total of 1647 cervical samples were analyzed with both tests. The agreement values were 96.2% for HPV detection, 99.6% for HPV-16 identification, and 99.7% for HPV-18 identification. All genotyping results from MeltPro HPV Test showed that HPV-52, HPV-58, and HPV-16 were the most common types in this study. Intra-laboratory reproducibility studies showed 97.8% agreement while inter-laboratory reproducibility studies showed 96.9% agreement for the MeltPro HPV Test. The MeltPro HPV Test and Cobas HPV Test are highly correlative and are useful for monitoring HPV infection.
[Mh] Termos MeSH primário: Alphapapillomavirus/classificação
Tipagem Molecular/métodos
Infecções por Papillomavirus/diagnóstico
Kit de Reagentes para Diagnóstico/normas
Neoplasias do Colo do Útero/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Alphapapillomavirus/genética
Alphapapillomavirus/isolamento & purificação
Colo do Útero/patologia
Colo do Útero/virologia
DNA Viral/genética
Feminino
Genótipo
Seres Humanos
Meia-Idade
Tipagem Molecular/instrumentação
Infecções por Papillomavirus/patologia
Infecções por Papillomavirus/virologia
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Neoplasias do Colo do Útero/patologia
Neoplasias do Colo do Útero/virologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Reagent Kits, Diagnostic)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1007/s00705-017-3645-1


  5 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29374885
[Au] Autor:Wang HL; Yang Z; Shen Y; Wang QL
[Ad] Endereço:Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.
[Ti] Título:[Clinical outcome of therapeutic cervical cerclage in short cervix syndrome].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;53(1):43-46, 2018 Jan 25.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the clinical effect of therapeutic cervical cerclage on short cervix syndrome for anti-premature birth in the second trimester. Totally 44 singleton pregnant patients were diagnosed as short cervix syndrome, which was cervical length ≤2.5 cm without cervical dilatation, and received treatment from January 2008 and July 2015 in Peking University Third Hospital were collected. Among them, 30 patients who received therapeutic cervical cerclage were defined as cerclage group and another 14 cases who received conservative treatment were defined as un-cerclage group. The days of conservative treatment, delivery rate of different gestational weeks, birth weight of newborns, neonatal survival rate within 7 days of birth were analyzed between the two groups. There were no significant differences between the two groups in days of pregnancy conservative treatment [103 (84-141) vs 105 (85-114) days], delivery weeks [38.0 (35.5-39.4) vs 38.5 (37.3-39.5) weeks], birth weight of newborns [3 120 (2 750-3 400) vs 3 130 (2 760-3 545) g], and survival rate of newborns [100% (30/30) vs 13/14]. The fetuses of both groups were all delivered after 28 weeks. There was no significant difference in accumulated delivery rate between the two groups after 32 weeks, 34 weeks, and 37 weeks, respectively (all 0.05) . The treatment of cervical cerclage is not superior to conservative means in single pregnancy of cervical length ≤2.5 cm without cervical dilatation. For such patients with short cervix syndrome, the treatment of cervical cerclage may not be necessary, but dynamic monitoring and search for the causing factors and prompt treatment are more important.
[Mh] Termos MeSH primário: Cerclagem Cervical
Colo do Útero/fisiopatologia
Resultado da Gravidez/epidemiologia
Incompetência do Colo do Útero/terapia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Peso ao Nascer
Parto Obstétrico
Feminino
Idade Gestacional
Seres Humanos
Recém-Nascido
Parto
Gravidez
Complicações na Gravidez
Segundo Trimestre da Gravidez
Nascimento Prematuro
Incompetência do Colo do Útero/diagnóstico
Incompetência do Colo do Útero/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567X.2018.01.009


  6 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369205
[Au] Autor:Lili E; Chatzistamatiou K; Kalpaktsidou-Vakiani A; Moysiadis T; Agorastos T
[Ad] Endereço:4th Department of Obstetrics and Gynecology.
[Ti] Título:Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up.
[So] Source:Medicine (Baltimore);97(4):e9719, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of the present cohort study was to assess the long-term (follow-up period up to 22 years) recurrence rate of preinvasive disease and the newly detected invasive disease rate in a cohort of women treated with excisional methods for high-grade cervical intraepithelial neoplasia (CIN).Women treated with large loop excision of the transformation zone (LLETZ) and cold knife conization (CKC) for histologically proven high-grade CIN were followed up for up to 22 years. Surgical specimens underwent histological examination and the status of endocervical as well as ectocervical margins was recorded. Follow-up protocol included conventional Pap test, colposcopy and pelvic examination at 3, 6, and 12 months after the initial treatment, and every 12 months thereafter, provided that the results were normal. In case of high-grade cytological findings and/or atypical colposcopic impression, multiple punch biopsies were taken in order to verify or exclude recurrent disease.In total, 804 women were followed for a mean time of 77.1 months (range: 6-266). LLETZ was used in 569 (70.7%) and CKC in 235 cases (29.2%). No woman developed invasive cervical cancer. Recurrent high-grade disease, developed in 9 women (1.1%, 95% confidence interval 0.5-2.2). Median treatment-to-recurrence time was 46.5 months (range: 6-235.3). One woman treated for squamous CIN2 on clear margins developed adenocarcinoma in situ 59.2 months post-treatment.Women having undergone excisional treatment for high-grade CIN indicate a very low risk for recurrent disease and potentially negligible risk for invasive cancer, provided that a strict and vigorous follow-up is offered after treatment.
[Mh] Termos MeSH primário: Neoplasia Intraepitelial Cervical/cirurgia
Colposcopia/métodos
Recidiva Local de Neoplasia/epidemiologia
Neoplasias do Colo do Útero/cirurgia
[Mh] Termos MeSH secundário: Adulto
Neoplasia Intraepitelial Cervical/patologia
Colo do Útero/patologia
Colo do Útero/cirurgia
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Gradação de Tumores
Recidiva Local de Neoplasia/patologia
Estudos Retrospectivos
Resultado do Tratamento
Neoplasias do Colo do Útero/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009719


  7 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277809
[Au] Autor:Okonogi N; Wakatsuki M; Kato S; Shiba S; Kobayashi D; Kiyohara H; Karasawa K; Ohno T; Nakano T; Kamada T; Shozu M; WORKING GROUP OF GYNECOLOGICAL TUMORS
[Ad] Endereço:Hospital, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan okonogi.noriyuki@qst.go.jp.
[Ti] Título:Long-term Outcomes of Carbon-ion Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix.
[So] Source:Anticancer Res;38(1):457-463, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: To evaluate the long-term outcomes of carbon-ion radiotherapy (C-ion RT) for locally advanced cervical squamous cell carcinoma (LAC-SqCC) in 2 prospective phase I/II studies. PATIENTS AND METHODS: In the first study, 14 patients were treated with 68.8-72.8 Gy (RBE)/24 fractions. In a subsequent study, 22 patients were treated with 64.0-72.0 Gy (RBE)/20 fractions while limiting the dose to the gastro-intestinal (GI) <60 Gy (RBE). RESULTS: The 10-year local control rates were 92% and 61% for the patients administered a total dose of 72.0-72.8 Gy (RBE) and 64.0-68.8 Gy (RBE), respectively. Two patients in the first study developed grade 3/4 rectal or bladder complications; however, no grade 3 or higher complications occurred in the second study. CONCLUSION: C-ion RT with a higher dose was associated with excellent LC in LAC-SqCC. Long-term safety was confirmed based on the establishment of dose constraints for the GI tract.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/radioterapia
Radioterapia com Íons Pesados/efeitos adversos
Neoplasias do Colo do Útero/radioterapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células Escamosas/patologia
Colo do Útero/patologia
Feminino
Seres Humanos
Meia-Idade
Estudos Prospectivos
Dosagem Radioterapêutica
Resultado do Tratamento
Neoplasias do Colo do Útero/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  8 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29182627
[Au] Autor:Cocuzza CE; Martinelli M; Sina F; Piana A; Sotgiu G; Dell'Anna T; Musumeci R
[Ad] Endereço:Department of Medicine and Surgery (School of Medicine), University of Milano-Bicocca, Monza, Italy.
[Ti] Título:Human papillomavirus DNA detection in plasma and cervical samples of women with a recent history of low grade or precancerous cervical dysplasia.
[So] Source:PLoS One;12(11):e0188592, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Circulating HPV DNA has been previously described in women with advanced stages of cervical cancer and has been suggested to be a prognostic marker of disease recurrences and metastases. Only a few studies have reported the presence of HPV DNA in bloodstream of patients with low grade or precancerous cervical lesions. This study aimed to define if HPV DNA could be detected in plasma samples of 120 women referred for a recent history of cervical dysplasia who presented with lesions ranging from High Squamous Intraepithelial Lesion (H-SIL) to regressed normal cytology. HPV DNA detection was carried out in both plasma and cervical samples using type-specific real-time quantitative PCR assays identifying oncogenic HPV 16, 18, 31, 33, 45, 51 and 52. Overall, 34.2% (41/120) of plasma samples were shown to be positive for HPV DNA detection; HPV 45 (46.3%), HPV-51 (29.6%), and HPV 16 (18.5%) were the most frequently identified genotypes. The rate of HPV detection in paired cervical and plasma samples increased with advancing disease stage, ranging from 15.4% in women with regressed lesions to 38.9% in women with HSIL; HPV 16 resulted the most common genotype identified in women found to be HPV DNA positive in both cervical and plasma samples. Moreover, HPV 16 showed the highest median viral load value in both cervical and plasma samples, with 48,313 copies/104 cells and 1,099 copies/ml, respectively. Results obtained in this study confirm that HPV DNA can be detected and quantified in plasma samples of women with asymptomatic cervical infection. Further knowledge on HPV dissemination through the blood stream of women with cervical lesions would be very important in better understanding the natural history of HPV infection as well as its potential role in other distant tumors.
[Mh] Termos MeSH primário: Alphapapillomavirus/genética
Neoplasia Intraepitelial Cervical/virologia
Colo do Útero/virologia
DNA Viral/metabolismo
[Mh] Termos MeSH secundário: Adulto
DNA Viral/sangue
Feminino
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188592


  9 / 21200 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29260206
[Au] Autor:Silver RM; Branch DW
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City.
[Ti] Título:Cervical Pessary to Prevent Preterm Birth.
[So] Source:JAMA;318(23):2299-2300, 2017 12 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Pessários
Nascimento Prematuro/prevenção & controle
[Mh] Termos MeSH secundário: Colo do Útero
Feminino
Seres Humanos
Recém-Nascido
Gravidez
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.18955


  10 / 21200 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448273
[Au] Autor:Wang JY; Healey T; Barker A; Brown B; Monk C; Anumba D
[Ad] Endereço:Academic Unit of Reproductive and Development Medicine, Jessop Wing, University of Sheffield and Sheffield Teaching Hospitals NHS Trust, Sheffield S10 2SF, United Kingdom.
[Ti] Título:Magnetic induction spectroscopy (MIS)-probe design for cervical tissue measurements.
[So] Source:Physiol Meas;38(5):729-744, 2017 May.
[Is] ISSN:1361-6579
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Gradiometers have the advantage of increasing measuring sensitivity, which is particularly useful in magnetic induction spectroscopy (MIS) for bio-impedance measurements. Traditional gradiometers use a pair of field sensing coils equally distant and on opposite sides of a drive coil, which provides high immunity to interference. In this paper, a ferrite-cored coaxial gradiometer probe of 29 mm diameter has been developed for measuring the impedance spectra of cervical tissues in vivo. APPROACH: It consists of a ferrite rod with outer ferrite confinement screening in order to eliminate the signals from surrounding tissue. The magnetic screening efficiency was compared with an air-cored gradiometer probe. For both gradiometer probes, a drive coil and two sensing coils were wound on a borosilicate glass former aligned coaxially with two sensing coils equidistant from the drive coil. The signal sensitivity of those two MIS gradiometers has been measured using saline samples with a conductivity range between 0.1 and 1.1 S m . Finite element methods using COMSOL Multiphysics have been used to simulate the distribution of sensitivity to conductivity over the face of each probe and with depth. MAIN RESULTS: The ferrite-cored probe has a sensitivity confined to the volume defined by the gap between the ferrite core and outer tube of ferrite while the air-cored probe without any magnetic shielding had a wide sensitivity over the face and the side of the probe. Four saline samples and one of distilled water with conductivities from 0.1 to 1.1 S m have been used to make conductivity measurements at frequencies of 50 kHz, 100 kHz, and 300 kHz. The measurement accuracy of the air-cored MIS probe was 0.09 S m at 50 kHz, improving to 0.05 S m at 300 kHz. For the ferrite-cored MIS probe, the measurement accuracy was 0.28 S m at 50 kHz, improving to 0.04 S m at 300 kHz. SIGNIFICANCE: In vivo measurements on human hand have been performed using both types of gradiometers and the conductivity is consistent with reported data.
[Mh] Termos MeSH primário: Colo do Útero/citologia
Espectroscopia Dielétrica/instrumentação
Fenômenos Magnéticos
[Mh] Termos MeSH secundário: Ar
Desenho de Equipamento
Feminino
Compostos Férricos
Análise de Elementos Finitos
Antebraço
Mãos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ferric Compounds); 1317-54-0 (ferrite)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171221
[Lr] Data última revisão:
171221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1088/1361-6579/aa6b4e



página 1 de 2120 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde